Syntax Bio expands Series A to $14.4M for cell therapy platform

What's the deal? Syntax BioDealroom has a profile for this one. Try Dealroom →, a Chicago-based synthetic biology company, has expanded its Series A to $14.4 million, bringing total funding past $25 million.

The startup will use the capital to advance its Cellgorithm platform and develop a pancreatic beta cell therapy for type 1 diabetes through pre-clinical proof-of-concept.

The round drew new backers including Draper Associates, Allegis CapitalDealroom has a profile for this one. Try Dealroom →, Mayo ClinicDealroom has a profile for this one. Try Dealroom →, and Illinois VenturesDealroom has a profile for this one. Try Dealroom →, alongside existing investors such as Astellas Venture Management, Illumina Ventures, and DCVC Bio.

Why now? Alongside the raise, Syntax Bio reshuffled its leadership. Co-founder Ryan Clarke moved from chief technology officer to chief scientific officer, while co-founder Nikolas Balanis stepped up to chief technology officer.

Both report to chief executive officer John Craighead, who joined in 2025.

"This financing enables us to accelerate sequential, endogenous gene activation technology, advance the first cell therapy discovered using the Cellgorithm platform and build collaborations to develop scalable regenerative medicines for serious diseases," Craighead said.

What could go wrong? The therapy remains pre-clinical, meaning years of trials stand between Syntax Bio and any approved treatment.

Regenerative medicine has long struggled to generate functional cells reliably at scale — the exact problem the company says it is solving.

The signal: Investors are betting on programmable cell therapies as the next frontier in treating serious diseases.

"Syntax's pioneering stem cell programming technology addresses the central constraint in regenerative medicine: the ability to reliably and efficiently generate functional cells at population scale," said Tim Draper, founding partner of Draper Associates.

The mix of venture capital, a major clinic, and state economic agencies signals growing conviction that synthetic biology can move from lab promise to scalable medicine.